Gsk (GSK) EBT (2009 - 2026)

Gsk (GSK) has 18 years of EBT data on file, last reported at $3.4 billion in Q3 2026.

• For the quarter ending Q3 2026, EBT changed N/A year-over-year to $3.4 billion; the trailing twelve-month figure through Sep 2026 stood at $12.0 billion (changed N/A YoY), and the FY2025 full-year result was $9.8 billion, up 121.5% from the prior year.
• EBT was $3.4 billion for Q3 2026 at Gsk, up from $475.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $5.3 billion in Q4 2025 to a low of $83.2 million in Q3 2024.
• A 5-year average of $2.5 billion and a median of $2.5 billion in 2025 frame the typical range for EBT.
• Across the five-year window, EBT plunged 96.33% in 2024 and surged 3885.36% in 2025, its largest moves.
• Gsk's EBT stood at $3.5 billion in 2022, then soared by 37.81% to $4.8 billion in 2023, then declined by 24.31% to $3.7 billion in 2024, then jumped by 45.27% to $5.3 billion in 2025, then slumped by 36.89% to $3.4 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were $3.4 billion in Q3 2026, $475.0 million in Q2 2026, and $2.9 billion in Q1 2026.